We are backed by a strong global consortium of leading investors

Discuss the opportunities

Partner up?

Get in contact

Our investors are integral to our mission of advancing groundbreaking therapies for patients with major unmet medical needs

With the support of an international consortium of leading investors, we are empowered to push the boundaries of science through our pipeline and technology. We benefit from the deep expertise and resources of our investors, who share our commitment to creating impactful therapeutics.

Validation of our approach from investors and big pharma

Confo Therapeutics is a company spun out of Professor Jan Steyaert’s lab at the VUB and the VIB.   As a clinical-stage company, we have established a strong financial position backed by an impressive consortium of global investors including: Ackermans & van Haaren, BioGeneration Ventures (BGV), Capricorn Health-tech Fund (CHF), Driehaus Capital Management, Fund+, MINTS (University of Michigan), Perceptive Advisors, PMV, Qbic, Quest for Growth (QfG), V-Bio Ventures, VIB and Wellington Partners.   Our deals with big pharma further validate the differentiating potential of our GPCR drug discovery engine.

Our investment partners

We are fortunate to have the backing of our top-tier funds who believe in our vision and support our mission.

Founding institutes

Confo Therapeutics was founded by VIB (Flander’s Institute of Biotechnology) and Vrije Universiteit Brussel (VUB) in 2015.

VIB is an entrepreneurial non-profit research institute, with a focus on strategic basic research in life sciences and operates in close partnership with the 5 universities in Flanders – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel, and Hasselt University.

Learn more

Vrije Universiteit Brussel (VUB) is a research-based and internationally-oriented university in Brussels. Ranked as one of the world’s top universities, it has award-winning research with more than 150 internationally recognized research teams.

Learn more

“We value our investors’ confidence and endeavor to advance our pipeline of GPCR-targeting medicines and deliver sustainable growth” Dieter Weinand | Chairman of the Board

“At Confo, we are committed to pushing the boundaries to develop groundbreaking GPCR-directed therapies that address critical health challenges” Cedric Ververken | Chief Executive Officer

“Our mission at Confo is to harness our cutting-edge technology to create transformative GPCR-directed therapies with the potential to improve outcomes for patients living with metabolic and endocrine conditions” Rob Scott | Independent Board Director

“Being part of Confo means being at the forefront of a revolution in GPCR drug discovery, where each breakthrough brings us closer to new therapies” Stephen Dowd | Chief Business Officer

Contact

Interested in becoming a part of our journey?

Our pipeline and platform technology are catalysts, transforming what’s possible and unlocking opportunities for value creation. Talk to us.

e-mail: [email protected]
tel. +32 9 396 74 00